Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A **preclinical to early clinical-stage small-molecule antineoplastic program** from **Translational Therapeutics** designed to inhibit or modulate the oncogenic translation factor **eukaryotic translation initiation factor 4E** and disrupt its reported \"gating\" role in malignant mRNA translation. The program is being positioned for **eIF4E-driven cancers**, described by the company as **4E cancers**, and has been presented as **IND-ready** and preparing for initiation of a **Phase 1/2** study in an orphan oncology setting. No distinct non-proprietary name, code name, brand name, formulation, or route of administration was identified from the provided materials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Translational Therapeutics eIF4E small molecule.